This phase I trial is evaluating an oral drug (venetoclax) with or without chemotherapy in children and young adults with relapsed or refractory malignancies.
This trial is treating multiple types of cancer including Acute Lymphoblastic Leukaemia (ALL), Acute Myeloid Leukaemia (AML), Non-Hodgkin's Lymphoma or Neuroblastoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
In this trial, Venetoclax will be administered orally once daily (QD) with various doses and dosing regimens, with or without chemotherapy at the discretion of the investigator.
Recruiting Hospitals Read More